CelLBxHealth has provided a trading update for the year ended 31 December 2025. The group is expected to deliver FY25 revenues of £1.4m, slightly below our estimates of £1.6m as a result of some sales contracts with an aggregate value of c£0.2m being deferred into 1Q26. The company’s cash position has also been further bolstered following completion of the recent (December 2025) equity financing, raising total gross proceeds of c£8.6m, with reported year-end cash of £7.3m. We have updated FY25E ....
